Cancer Treatment Brands

Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.

Groundbreaking anti-VEGF biologic cancer therapy (bevacizumab) developed by Genentech and owned by Roche, FDA approved February 26, 2004, that reached peak global sales of $7.1 billion in 2019 and now faces biosimilar competition including Mvasi (Amgen) and multiple other approved alternatives.

Prescription immunotherapy medication for treating various cancers by activating the immune system, manufactured and marketed by Merck & Co.